Larimar Therapeutics宣布Nomlabofusp获FDA突破性疗法认定

投资观察
Feb 24

Larimar Therapeutics Inc 披露,其候选药物Nomlabofusp用于治疗弗里德赖希共济失调(FA)已获得美国食品药品监督管理局(FDA)授予的突破性疗法认定。公司同时重申,计划于2026年6月提交生物制品许可申请(BLA)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10